NVCR NovoCure Ltd
- Stocks
- Healthcare
- NASDAQ: NVCR
Price (delayed)
$11.73
Market cap
$1.31B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.56
Enterprise value
$1.86B
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating
Highlights
The gross profit has increased by 15% YoY
The company's revenue rose by 15% YoY
The company's quick ratio has shrunk by 78% YoY
The net income has contracted by 4.1% from the previous quarter
Key stats
What are the main financial stats of NVCR
Market
Valuations
Earnings
Shares outstanding
111.8M
Market cap
$1.31B
Enterprise value
$1.86B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.74
Price to sales (P/S)
2.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.95
Revenue
$630.16M
Gross profit
$481.33M
Operating income
-$172.78M
Net income
-$170.95M
EBIT
-$172.78M
EBITDA
-$160.45M
Free cash flow
-$80.4M
Per share
Balance sheet
Liquidity
EPS
-$1.56
EPS diluted
-$1.56
Free cash flow per share
-$0.72
Book value per share
$3.13
Revenue per share
$5.65
TBVPS
$11.17
Total assets
$1.25B
Total liabilities
$896.43M
Debt
$700.25M
Equity
$349.44M
Working capital
$333.67M
Debt to equity
2
Current ratio
1.45
Quick ratio
1.39
Net debt/EBITDA
-3.42
Margins
Efficiency
Dividend
EBITDA margin
-25.5%
Gross margin
76.4%
Net margin
-27.1%
Operating margin
-27.4%
Return on assets
-13.8%
Return on equity
-47.7%
Return on invested capital
-16.9%
Return on capital employed
-34.8%
Return on sales
-27.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVCR stock price
How has the NovoCure stock price performed over time
Intraday
1.21%
1 week
5.39%
1 month
-30.14%
1 year
-37.97%
YTD
-60.64%
QTD
-34.1%
Financial performance
How have NovoCure's revenue and profit performed over time
Revenue
$630.16M
Gross profit
$481.33M
Operating income
-$172.78M
Net income
-$170.95M
Gross margin
76.4%
Net margin
-27.1%
NovoCure's operating margin has increased by 18% YoY but it has decreased by 2.2% QoQ
The gross profit has increased by 15% YoY
The company's revenue rose by 15% YoY
NovoCure's net margin has increased by 12% YoY but it has decreased by 2.7% from the previous quarter
Price vs fundamentals
How does NVCR's price correlate with its fundamentals
Growth
What is NovoCure's growth rate over time
Valuation
What is NovoCure stock price valuation
P/E
N/A
P/B
3.74
P/S
2.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.95
NVCR's EPS is down by 3.3% since the previous quarter
The price to book (P/B) is 79% lower than the 5-year quarterly average of 17.8 and 40% lower than the last 4 quarters average of 6.2
The equity has declined by 3.5% since the previous quarter and by 3.4% year-on-year
NVCR's price to sales (P/S) is 85% lower than its 5-year quarterly average of 13.6 and 42% lower than its last 4 quarters average of 3.6
The company's revenue rose by 15% YoY
Efficiency
How efficient is NovoCure business performance
NovoCure's ROIC has decreased by 23% YoY and by 17% from the previous quarter
NVCR's return on sales is up by 18% year-on-year but it is down by 2.2% since the previous quarter
The company's return on assets rose by 5% YoY but it fell by 3.8% QoQ
NovoCure's return on equity has decreased by 4.8% QoQ and by 4.4% YoY
Dividends
What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVCR.
Financial health
How did NovoCure financials performed over time
NovoCure's total assets is 39% more than its total liabilities
The company's quick ratio has shrunk by 78% YoY
The company's current ratio has shrunk by 78% YoY
NovoCure's debt is 100% more than its equity
NVCR's debt to equity is up by 7% YoY and by 4.2% QoQ
NovoCure's debt has increased by 3.7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.